NCT07101939View on ClinicalTrials.gov

A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During, and Post-semaglutide Therapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

June 23, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

September 30, 2026

Conditions
ObesityMuscle Loss
Interventions
DRUG

(S)-pindolol benzoate

(S)-pindolol benzoate (ACM-001.1) immediate release tablet containing (S)-pindolol benzoate administered BID.

DRUG

Semaglutide

Semaglutide, solution for injection in pre-filled pen

DRUG

Placebo to (S)-pindolol benzoate

Placebo to ACM-001.1 immediate release tablet administered BID

Trial Locations (5)

Unknown

RECRUITING

Clinical Hospital Center 'Dr Dragisa Misovic - Dedinje', Belgrade

RECRUITING

Clinical Hospital Center Bezanijska kosa, Belgrade

RECRUITING

University Clinical Center of Serbia, Belgrade

RECRUITING

University Clinical Center Kragujevac, Kragujevac

RECRUITING

Ubiversity Clinical Center of Vojvodina, Novi Sad

Sponsors
All Listed Sponsors
collaborator

SCIRENT Clinical Research and Science d.o.o.

UNKNOWN

lead

Actimed Therapeutics Ltd

INDUSTRY